Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy

Table 1 Patient characteristics

	Patients, No. (%)
	All patients (N = 186)
Age, median (range), y	68 (32–83)
Sex
Male	143 (76.9)
Female	43 (23.1)
ECOG-PS
0 or 1	134 (72.0)
≥2	52 (28.0)
Smoking status
Never	36 (19.4)
Current or former	130 (70.0)
Unknown	20 (10.8)
Stage
III	29 (15.6)
IV	116 (62.4)
Recurrence	41 (22.0)
Primary organ
Lung/pleura	74 (39.8)
Kidney/urinary tract	58 (31.2)
Skin	10 (5.4)
Gastrointestinal tract	28 (15.1)
Head and neck	16 (8.6)
History of prior thoracic radiotherapy	34 (18.3)
Prior PD-1/PD-L1 inhibitors
Nivolumab	89 (47.8)
Pembrolizumab	64 (34.4)
Atezolizumab	22 (11.8)
Durvalumab	6 (3.2)
Avelumab	5 (2.7)
Prior ICI treatment
Monotherapy	126 (67.7)
Immunochemotherapy	39 (21.0)
Combination with CTLA-4 blockade therapy with or without chemotherapy	7 (3.8)
Combination with molecular targeted agents	14 (7.5)
irAEs in prior ICI regimens
ICI-induced ILD	18 (9.7)
Others	62 (33.3)
Duration of ICI therapy, median (range), m	4.0 (0.5–39.9)
Post-ICI antineoplastic therapy
Cytotoxic chemotherapy alone	106 (57.0)
Molecular targeted therapy with or without cytotoxic agents^a	80 (43.0)
Treatment line
2nd	69 (37.1)
3rd	61 (32.8)
≥4th	56 (30.1)
Duration of post-ICI antineoplastic therapy, median (range), m	3.0 (0.5–39.9)

^aTwenty-three patients were treated with molecular targeted therapy combined with cytotoxic agents including antibody–drug conjugates
CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; ECOG: Eastern Cooperative Oncology Group; ICIs: immune checkpoint inhibitors; ILD: interstitial lung disease; irAEs: immune-related adverse events; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; PS: performance status

ISSN: 1465-993X